文献速递糖尿病性腺与生殖内分泌

1型糖尿病分娩期及产后早期使用自动胰岛素输送:CIRCUIT随机对照试验预设分析

Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

CIRCUIT试验预设分析比较1型糖尿病孕妇分娩期及产后早期闭环系统与标准治疗的血糖有效性和安全性。分娩前24小时闭环组孕期目标血糖范围时间79.6%高于标准组64.8%(校正均差13.2个百分点,95%CI 5.2-21.2),产后第一周低血糖时间更少(1.7% vs 3.2%)。无严重低血糖或酮症酸中毒安全信号。

要点

  • 分娩前24小时闭环组孕期目标血糖范围时间达79.6%,高于标准组64.8%。
  • 产后第一周闭环组血糖<70 mg/dL时间1.7%,少于标准组3.2%。
  • 闭环组无母体严重低血糖,标准组产后发生1例;两组均无酮症酸中毒。

核心结论

  • 该闭环系统在分娩期及产后早期血糖控制优于标准治疗且无安全性顾虑。
  • 结合既往结果,支持该闭环系统在整个孕期、分娩及产后早期使用。

研究设计与样本

  • CIRCUIT随机对照试验的预设分析,比较1型糖尿病分娩期及产后早期闭环系统与标准治疗。
  • 主要结局为分娩前24小时经连续血糖监测的孕期特定血糖范围(63-140 mg/dL)时间百分比。

主要发现

  • 分娩前24小时44例闭环组中39例(89%)继续使用闭环系统。
  • 分娩期静脉胰岛素使用:闭环组1例(2%),标准组20例(45%),P<0.001。
  • 分娩前24小时孕期目标血糖范围时间闭环组79.6% vs 标准组64.8%,校正均差13.2个百分点(95%CI 5.2, 21.2)。
  • 产后第一周血糖<70 mg/dL时间闭环组1.7% vs 标准组3.2%,校正均差-1.8个百分点(95%CI -0.9 to -2.7)。
  • 闭环组无母体严重低血糖,标准组产后发生1例;两组均无糖尿病酮症酸中毒。

关键数值与推荐

  • 孕期特定血糖目标范围为63-140 mg/dL。
  • 主要结局为分娩前24小时该范围内时间百分比;关键次要结局为产后第一周血糖<70 mg/dL时间百分比。

临床怎么用

  • 分娩期及产后早期可继续使用该闭环系统以改善血糖控制并减少静脉胰岛素使用。
  • 产后第一周闭环系统有助于减少低血糖时间,且未增加严重低血糖或酮症酸中毒风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Following the demonstrated improvement in pregnancy glycemia with Control-IQ closed loop in the Closed-Loop Insulin Delivery by Glucose Responsive Computer Algorithms in Type 1 Diabetes Pregnancies (CIRCUIT) trial, we compared intrapartum and early postpartum glycemic effectiveness and safety with standard care in type 1 diabetes. RESEARCH DESIGN AND METHODS: The primary outcome of this prespecified analysis was percentage of time in pregnancy-specific glucose range (63-140 mg/dL) during the 24 h prior to childbirth, measured by continuous glucose monitoring. A key secondary outcome was percentage of time at <70 mg/dL in the first postpartum week, with additional secondary outcomes including continuous glucose monitoring metrics through 6 weeks postpartum. Analyses were adjusted for baseline measure, insulin delivery mode, and site. RESULTS: In the intrapartum period (24 h before delivery), 39 of 44 (89%) participants continued closed loop. Intravenous insulin was used intrapartum by one (2%) closed-loop participant and 20 (45%) standard-care participants (P < 0.001). Intrapartum closed-loop users spent more time in pregnancy-specific glucose range (79.6% vs. 64.8%) than the standard-care group (mean adjusted difference 13.2 percentage points; 95% CI 5.2, 21.2). In the first postpartum week, the closed-loop group spent less time <70 mg/dL (1.7% vs. 3.2%; mean adjusted difference -1.8 percentage points; 95% CI -0.9 to -2.7) compared with the standard-care group. No maternal severe hypoglycemia occurred in the closed-loop group, while one episode occurred in the standard-care group postpartum. No diabetic ketoacidosis occurred in either group. CONCLUSIONS: Use of this closed-loop system resulted in superior intrapartum and early postpartum glycemia compared with standard care without safety concerns. Together with previous results, this supports use of this closed-loop system throughout pregnancy, labor, and the early postpartum period.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Donovan LE, Lemieux P, Yamamoto JM, et al. Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial. Diabetes Care. 2026. PMID: 42201836. doi:10.2337/dc26-0470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。